大剂量托瑞米芬联合NP方案治疗晚期非小细胞肺癌的近期疗效观察

目的探讨大剂量托瑞米芬增敏长春瑞滨和顺铂（NP方案）I治疗非小细胞肺癌（NSCLC）的近期疗效。方法人组患者随机分为两组。治疗组采用大剂量托瑞米芬＋NP方案治疗。对照组仅用NP方案治疗。治疗组的患者在口服托瑞米芬后第2天和第8天抽血测定托瑞米芬血清浓度。结果治疗组PR7例，SD13例，PD2例，有效率为31．8％。对照组PR1例，SD17例，PD3例，有效率为4．7％；治疗组与对照组相比，有效率差异有统计学意义（P〈0．05）。二组不良反应无明显差异。托瑞米芬血清浓度在第2天和第8天均超过5μmol／L。结论通过随机对照研究证实，大剂量托瑞米芬联合NP方案治疗晚期NSCLC安全有效。

Therapeutic effect of high-dose toremifene and NP regimen in advanced NSCLC

Objective To investigate therapeutic effect of high-dose toremifene and NP regimen in advanced NSCLC. Methods Advanced NSCLC patients were divided into 2 groups randomly. The treatment group was given high-dose toremifene plus NP chemotherapy. The control group was given NP chemotherapy only. The treatment group was measured plasma level of toremifene in the second day and the eighth day after using toremifene. Results There were PR 1 ,SD17 and PD 3 in the control group and the response rate was 4. 7%. There were PR 7 ,SD13 and PD 2 in the treatment group and the response rate was 31.8%. The difference between the response rate of two groups was significant （ P 〈 0. 05 ）. The toxicity between the two groups was not significantly different. Plasma level of toremifene is over 5 μmol/L in the second day and the eighth day. Condusion The clinical study indicates that high-dose toremifene plus NP regimen is safe and effective in the treatment of advancde NSCLC.